CARVYKTI®? (ciltacabtagene autoleucel; cilta-cel) significantly improved progression-free survival and deepened responses versus two standard…

Posted: June 4, 2024 at 2:49 am

73 percent reduction in risk of disease progression or death seen with cilta-cel in the CARTITUDE-4 study in a subset of patients who had early relapse after initial multiple myeloma therapy1

Continue reading here:
CARVYKTI®? (ciltacabtagene autoleucel; cilta-cel) significantly improved progression-free survival and deepened responses versus two standard...

Related Posts